Clinical Trial Search

Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change

Primary: Cerebral Blood Flow — 1.7; 1.3 percentage of signal intensity change

Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL

Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml

Primary: Glucagon Response to Acute Hypoglycaemia — 1.33; 1.0; 1.33 pmol/L — p=1.0

Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460

Primary: Psychomotor Speed — 48.7; 56.6 score on a scale

Primary: Maximal Glucagon Concentration During Hypoglycemia — 19.9; 22.5; 82.7 pg/mL

Primary: Hemoglobin A1c — 7.99; 7.69; 7.69; 7.58 percentage of glycated hemoglobin — p==0.001

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: Glucagon (pg/mL) — 76; 74; 53; 56 pg/mL

Primary: Fear of Hypoglycemia — 54.3; 58.7; 35.29; 49.0 units on a scale

Primary: % Time Within Target Range — 57.7; 58.2 percentage of time in range

Primary: Hypoglycemic Events — 0.27; 1.0; 0.18; 0.18 events/patient

Primary: Change in HbA1c — 0.32; 0.35; 0.52 percent of glycated hemoglobin

Primary: Endogenous Glucose Production — .66 [mg/(kgxmin)]

Primary: Hypoglycemia Fear Scale Score (HFS_2) — 21.4; 38.6 units on a scale

Primary: Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl — 1015; 4375.68 mg/dl/min

Primary: Feasibility of Usage — 168 minutes/week

Primary: Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl — -3.8 percentage of time

Primary: Number of All Consented Participants — 12; 12 Participants

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: Number of Subjects With a Positive Glucose Response — 76; 78 Participants

Primary: Hypoglycemia Fear Survey — 75.94; 70.78 units on a scale

Primary: Hypoglycemic Events — 1.08; 0.4; 1.4; 1.6 events/admission per patient

Primary: Hypoglycemia Incidence — 53; 10 participants — p=<0.001

Primary: Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores — -0.1215 Correlation coefficient — p=0.0002

Primary: Change Between Pre and Post Challenge Glucose Variability — 0.51; 1.62; 3.71; 0.97 score on a scale

Primary: Mean Glucose — 182; 165; 181; 165 mg/dl

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage